Efficacy News and Research

RSS

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results reported at the ESMO Congress 2022 from the phase 3 M14TIL trial.

12 Sep 2022

A direct side-by-side comparison of all available COVID-19 vaccines

In a recent study posted to the medRxiv* preprint server, researchers assessed immune responses to homologous and heterologous coronavirus disease 2019 (COVID-19) vaccine combinations among Córdoba, Spain residents.

11 Sep 2022

Discovery of antibodies that may eliminate the need for COVID vaccines

...

11 Sep 2022

A new monkeypox vaccine is needed to prevent global transmission

In a recent study published in the journal Vaccines, scientists reviewed all relevant literature to find the available vaccines and therapeutics to prevent MPV.

11 Sep 2022

ACTG announces the initiation of trial evaluating the safety and efficacy of monkeypox treatment

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which expanded its focus to conduct research into COVID-19, today announced the initiation of STOMP (Study of Tecovirimat for Human Monkeypox Virus), or A5418, a phase 3, randomized, placebo-controlled, double-blind trial evaluating the safety and efficacy of tecovirimat for the treatment of human monkeypox.

9 Sep 2022

St. Baldrick's Scholar grant awarded to CU researcher for investigating new drug to treat infant leukemia

As part of its ongoing efforts to eradicate childhood cancers, the St. Baldrick's Foundation has awarded University of Colorado Cancer Center member Kelly Faulk, MD, a St. Baldrick's Scholar grant to investigate a new method for treating infant leukemia.

9 Sep 2022

Phase 3 clinical trial commences to evaluate antiviral for monkeypox

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States.

9 Sep 2022

Vaccination hesitancy more prominent among pregnant women of lower socioeconomic status

A questionnaire of 1,899 pregnant women nationwide representing all 50 states reveals that during the Covid-19 pandemic if a pregnant woman had lower socioeconomic status and/or were African American, she was less likely to have the intention of taking a Covid-19 vaccine or actually receiving it.

9 Sep 2022

The evolution of humoral immune responses over the course of Epstein-Barr virus infection

Researchers explored probable humoral immune mechanisms related to EBV curtailment, besides neutralization, by a systematic emphasis on antibody fragment crystallizable-functional activities over the course of EBV infections.

9 Sep 2022

Children with Bell's palsy recover without medication within six months

Most children with a condition that causes a temporary weakness or paralysis of the muscles in the face recover without medication within six months, according to a new study.

9 Sep 2022

All SARS-CoV-2 variants neutralized by a potent new antibody

Researchers describe a mouse model used to generate a VH1-2 heavy chain (HC)- and Vκ1-33 light chain (LC)-based recombinant antibody that broadly neutralized all severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including the newly emergent Omicron sub-variant BA.5.

9 Sep 2022

Booster vaccination maintains high efficacy against malaria in African children

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M™ - which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021.

9 Sep 2022

Study provides a potential game-changer in assessing treatment response in pancreatic cancer patients

The statistics for pancreatic cancer are sobering. With a five-year survival rate of only 9%, incidence of the most common type, pancreatic ductal adenocarcinoma (PDAC), is growing and projected to be the second cause of cancer deaths by 2030.

8 Sep 2022

Can preclinical COVID-19 models help unlock mystery of long-COVID?

In a recently published article in the journal PLOS PATHOGENS, scientists have summarized acute and prolonged clinical manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The review also provides an overview of the potency and utility of preclinical animal models to understand the mechanistic details of acute and long coronavirus disease 2019 (COVID-19).

8 Sep 2022